Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients with Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies the side effects of bevacizumab and anetumab ravtansine or paclitaxel in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that does not respond to treatment (refractory). Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Anetumab ravtansine is a drug that targets a protein in the body called mesothelin, which can be found in some ovarian, pancreatic and other tumors. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving bevacizumab and anetumab ravtansine or paclitaxel may work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
Olaparib and Entinostat in Treating Patients with Recurrent, Platinum-Refractory or Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Multiple Cancer Types
This phase I / II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Tumor samples from patients will be tested for a specific change in their genetic materials (DNA) called homologous recombination deficiency (HRD). Patients who lack this genetic change will be eligible to participate in this study. Olaparib and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.